Deltex Medical Group plc
Interim results to 30 June 2021 Company Update
20 September 2021
Andy Mears
Chief Executive Officer
Natalie Wettler
Group Finance Director
© Deltex Medical Group plc (2021). All rights reserved.
Deltex Medical
Why monitor haemodynamics? Why Deltex Medical?
Haemodynamic monitoring
- Visualisation & measurement of circulating blood volume, which is a function of blood flow, blood pressure and resistance
Criticality of blood flow
If circulating blood flow is not optimised during surgery, or in intensive care then:
- inadequate blood and oxygen supply to vital organs (e.g. gut, kidneys, liver) can occur
- increases the risk of organ under-perfusion & harm
- increased risk of over-perfusion and patient injury
Scientific evidence
The use of Deltex Medical's
TrueVue Doppler haemodynamic monitoring technology has been proven in 24 randomised controlled trials (RCTs) to:
- reduce avoidablecomplications, including major ones such as Acute Kidney Injuries (AKIs) & Surgical Site Infections (SSIs)
- improve outcomes for both high risk and low-to-moderate risk patients
- give rise to shorter patient length of stay
- lower costs to healthcare systems
- improve patient safety
Deltex Medical TrueVue System
The only haemodynamic monitoring technology that can independently measure both blood flow & blood pressure across each and every heart beat
TrueVue Platform:
- Doppler
- Impedance
- PressureWave
- core technology within Deltex Medical's portfolio
- high precision, beat-to-beatreal-time information on the patient's circulating blood volume
- global 'gold standard' for precision haemodynamic monitoring
- high margin, single-use disposable ultrasound probe
2
Increasing pressure from health systems, regulators, patient safety advocates & payers to reduce risks to patients, with a particular focus on 'avoidablecomplications'
"Navigating haemodynamics - see what we see"
Deltex Medical
Effect of COVID-19 on our business
By the end of 2019 we had turned the business around and had reported positive EBITDA.
But then COVID-19 hit
- pre pandemic c.80% of Deltex Medical's revenues were generated from elective surgery
- the effect of COVID-19 on elective surgery - and hence Deltex Medical - has been substantial
3
"Navigating haemodynamics - see what we see"
Deltex Medical
Summary P&L information to 30 June, 2021
£000 | 30 June 2021 | 30 June 2020 | ||||
Probe revenues | 923 | 86% | 1,044 | 90% | ||
Other revenues | 149 | 14% | 113 | 10% | ||
Total revenues | 1,072 | 100% | 1,157 | 100% | ||
Gross margin | 691 | 64% | 756 | 65% | ||
Administrative costs | (777) | (578) | ||||
Sales & distribution costs | (466) | (550) | ||||
R&D and Q&R costs | (117) | (186) | ||||
Total overheads | (1,360) | (1,314) | ||||
Adjusted EBITDA* | (242) | (241) | ||||
Operating profit / (loss) | (451) | (490) | ||||
Loss for the period | (524) | (574) |
4 * Earnings before interest, tax, depreciation and amortisation, share-based payments, non-executive directors' fees and other items (Note 5 in the interims)
"Navigating haemodynamics - see what we see"
Deltex Medical
Summary balance sheet information at 30 June 2021
£000 | 30 Jun | 30 Jun | ||||
2021 | 2020 | |||||
Borrowings | ||||||
Property, plant & | 271 | 344 | ||||
equipment | Trade & other payables | |||||
Intangible assets | 2,756 | 2,696 | ||||
Total current liabilities | ||||||
Financial assets at | 157 | 159 | Borrowings | |||
amortised cost | ||||||
Trade & other payables | ||||||
Total non-curr. assets | 3,184 | 3,199 | ||||
Provisions | ||||||
Inventories | 812 | 1,000 | ||||
Total non-curr. liabilities | ||||||
Trade & other | 392 | 655 | ||||
Total liabilities | ||||||
receivables | ||||||
Other current assets | 212 | 431 | ||||
Cash & cash equivalents | 553 | 568 | ||||
Total current assets | 1,969 | 2,654 | ||||
Total assets | 5,153 | 5,853 | ||||
Net assets | ||||||
30 Jun | 30 Jun | |
2021 | 2020 | |
(163) | (77) | |
(1,527) | (2,185) | |
(1,690) | (2,262) | |
(1,010) | (1,092) | |
(252) | (300) | |
(51) | (65) | |
(1,313) | (1,457) | |
(3,003) | (3,719) | |
2,150 2,134
5
"Navigating haemodynamics - see what we see"
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original document
- Permalink
Disclaimer
Deltex Medical Group plc published this content on 20 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 20 September 2021 06:01:02 UTC.